
1. lancet infect dis. 2018 aug;18(8):874-883. doi: 10.1016/s1473-3099(18)30309-8.
epub 2018 jun 13.

antimalarial activity single-dose dsm265, novel plasmodium dihydroorotate
dehydrogenase inhibitor, patients uncomplicated plasmodium falciparum 
plasmodium vivax malaria infection: proof-of-concept, open-label, phase 2a
study.

llanos-cuentas a(1), casapia m(2), chuquiyauri r(3), hinojosa jc(2), kerr n(4),
rosario m(5), toovey s(4), arch rh(5), phillips ma(6), rozenberg fd(7), bath
j(7), ng cl(7), cowell an(8), winzeler ea(9), fidock da(10), baker m(11), möhrle 
jj(4), hooft van huijsduijnen r(4), gobeau n(4), araeipour n(4), andenmatten
n(4), rückle t(12), duparc s(13).

author information: 
(1)universidad peruana cayetano heredia, lima, peru.
(2)asociación civil selva amazónica, iquitos, peru.
(3)universidad peruana cayetano heredia, lima, peru; asociación civil selva
amazónica, iquitos, peru.
(4)medicines malaria venture, geneva, switzerland.
(5)takeda development center americas inc, cambridge, ma, usa.
(6)department biochemistry, university texas southwestern medical centre,
dallas, tx, usa.
(7)department microbiology immunology, columbia university medical center,
new york, ny, usa.
(8)school medicine, university california san diego, la jolla, ca, usa.
(9)school medicine, university california san diego, la jolla, ca, usa;
skaggs school pharmacy pharmaceutical sciences, university california
san diego, la jolla, ca, usa.
(10)department microbiology immunology, columbia university medical
center, new york, ny, usa; division infectious diseases, department of
medicine, columbia university medical center, new york, ny, usa.
(11)glaxosmithkline consumer healthcare switzerland ag, rotkreuz, switzerland.
(12)geneuro sa, geneva, switzerland.
(13)medicines malaria venture, geneva, switzerland. electronic address:
duparcs@mmv.org.

erratum in
    lancet infect dis. 2018 aug;18(8):829.

comment in
    lancet infect dis. 2018 aug;18(8):819-820.

background: dsm265 novel, long-duration inhibitor plasmodium
dihydroorotate dehydrogenase (dhodh) excellent selectivity human dhodh 
and activity blood liver stages plasmodium falciparum. study 
aimed assess efficacy dsm265 patients p falciparum or
plasmodium vivax malaria infection.
methods: proof-of-concept, open-label, phase 2a study conducted the
asociación civil selva amazónica iquitos, peru. patients aged 18-70 years,
weighing 45-90 kg, clinical malaria (p falciparum p vivax
monoinfection) fever within previous 24 h eligible. exclusion
criteria clinical laboratory signs severe malaria, inability take
oral medicine, use antimalarial treatment preceding 14 days. 
patients divided cohorts p falciparum (cohort a) p
vivax (cohort b) infection. two initial cohorts received single oral doses 400
mg dsm265. patients followed efficacy 28 days safety 35
days. cohorts received escalated de-escalated doses dsm265, after
safety efficacy assessment initial dose. primary endpoints were
the proportion patients achieving pcr-adjusted adequate clinical and
parasitological response (acpr) day 14 patients infected p falciparum
and proportion patients achieving crude cure day 14 those
infected p vivax. cohort success, criteria dose escalation, was
defined acpr (p falciparum) crude cure (p vivax) least 80% of
patients cohort. primary analysis done intention-to-treat
population (itt) per-protocol population, safety analyses done
in patients received study drug. study registered at
clinicaltrials.gov (nct02123290).
findings: jan 12, 2015, dec 2, 2015, 45 peruvian patients (24 p 
falciparum [cohort a] 21 p vivax [cohort b] infection) sequentially
enrolled. patients p falciparum malaria per-protocol population, 
all 11 (100%) 400 mg group eight (80%) ten 250 mg group
achieved acpr day 14. itt analysis, 11 (85%) 13 400 mg group 
and eight (73%) 11 250 mg group achieved acpr day 14. the
patients p vivax malaria, primary endpoint met. the
per-protocol analysis, none four patients 400 mg, three (50%) six
who 600 mg, one (25%) four 800 mg dsm265 achieved crude cure
at day 14. itt analysis, none five 400 mg group, three (33%) 
nine 600 mg group, one (14%) seven 800 mg group achieved
crude cure day 14. 28-day extended observation p falciparum
patients, resistance-associated mutation gene encoding dsm265 target
dhodh observed two four recurring patients. dsm265 well tolerated. 
the common adverse events pyrexia (20 [44%] 45) headache (18
[40%] 45), common symptoms malaria, patients 
treatment-related serious adverse events adverse events leading study
discontinuation.
interpretation: single dose dsm265, p falciparum parasitaemia was
rapidly cleared, whereas p vivax, dsm265 showed less effective clearance 
kinetics. long duration action provides potential prevent
recurrence p falciparum treatment single dose, be
further assessed future combination studies.
funding: global health innovative technology fund, bill & melinda gates
foundation, national institutes health (r01 ai103058), wellcome trust,
and uk department international development.

copyright © 2018 author(s). published elsevier ltd. open access
article cc 4.0 license. published elsevier ltd.. rights
reserved.

doi: 10.1016/s1473-3099(18)30309-8 
pmcid: pmc6060173
pmid: 29909069  [indexed medline]

